Clinical Research Directory
Browse clinical research sites, groups, and studies.
Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis
Sponsor: Glostrup University Hospital, Copenhagen
Summary
This study, iPROACT-MS, is part of the iPROACT group of clinical trials aiming to investigate the effects of oral supplementation with indole-3-propionic acid (IPA) in humans. IPA is naturally produced as a gut bacterial metabolite with the amino acid tryptophan as substrate. The primary aim of iPROACT-MS is to investigate whether patients with relapsing-remitting multiple sclerosis (RRMS) can benefit from supplementation with IPA. The hypothesis is that supplementation with IPA will protect against MS-related disease activity, neurodegeneration and metabolic abnormalities. Secondary, iPROACT-MS aims at elucidating the complex relationships between lifestyle, gut microbial factors, inflammation, oxidative stress, metabolic health, MS disease severity and MS disease activity.
Official title: Indole-3-PROpionic Acid Clinical Trials - Multiple Sclerosis (iPROACT-MS)
Key Details
Gender
All
Age Range
18 Years - 65 Years
Study Type
INTERVENTIONAL
Enrollment
220
Start Date
2026-01-26
Completion Date
2028-07-15
Last Updated
2026-01-28
Healthy Volunteers
No
Interventions
Placebo
Two capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Placebo capsules are taken orally.
Indole-3-propionic acid (IPA)
Two capsules are taken every morning and two capsules are taken every evening for 27 consecutive months. Active capsules are taken orally and contain 250 mg of IPA each resulting in a total daily dose of 1000 mg of IPA.
Locations (1)
Glostrup Hospital
Glostrup Municipality, Denmark